Article

 

Cardiac Metabolic Pathways Affected in the Mouse Model of Barth Syndrome Open Access Deposited

Downloadable Content

Download PDF
Download Adobe Acrobat Reader
Date Uploaded: 03/03/2017
Date Modified: 04/07/2017

Cardiolipin (CL) is a mitochondrial phospholipid essential for electron transport chain (ETC) integrity. CL-deficiency in humans is caused by mutations in the tafazzin (Taz) gene and results in a multisystem pediatric disorder, Barth syndrome (BTHS). It has been reported that tafazzin deficiency destabilizes mitochondrial respiratory chain complexes and affects supercomplex assembly. The aim of this study was to investigate the impact of Taz-knockdown on the mitochondrial proteomic landscape and metabolic processes, such as stability of respiratory chain supercomplexes and their interactions with fatty acid oxidation enzymes in cardiac muscle. Proteomic analysis demonstrated reduction of several polypeptides of the mitochondrial respiratory chain, including Rieske and cytochrome c1 subunits of complex III, NADH dehydrogenase alpha subunit 5 of complex I and the catalytic core-forming subunit of F0F1-ATP synthase. Taz gene knockdown resulted in upregulation of enzymes of folate and amino acid metabolic pathways in heart mitochondria, demonstrating that Tazdeficiency causes substantive metabolic remodeling in cardiac muscle. Mitochondrial respiratory chain supercomplexes are destabilized in CL-depleted mitochondria from Taz knockdown hearts resulting in disruption of the interactions between ETC and the fatty acid oxidation enzymes, very long-chain acyl-CoA dehydrogenase and long-chain 3-hydroxyacylCoA dehydrogenase, potentially affecting the metabolic channeling of reducing equivalents between these two metabolic pathways. Mitochondria-bound myoglobin was significantly reduced in Taz-knockdown hearts, potentially disrupting intracellular oxygen delivery to the oxidative phosphorylation system. Our results identify the critical pathways affected by the Taz-deficiency in mitochondria and establish a future framework for development of therapeutic options for BTHS.

Creator
License
Subject
Submitter
College
Department
Date Created
Journal Title
  • PLoS ONE
Language
Note
  • This work was part of a pilot "mediated-deposit model" where library staff found potential works, later submitted for faculty review

Digital Object Identifier (DOI)

Identifier: 10.1371/journal.pone.0128561
Link: http://dx.doi.org/10.1371/journal.pone.0128561

This DOI link is the best way for others to cite your work.

Relationships

Items

Permanent link to this page: https://scholar.uc.edu/show/bc3870894